Chronic Back Pain

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Daewon PharmaKorea - Hwaseong

1 program

DW-330SR2Phase 31 trial

Active Trials

NCT02375633Completed166

Creative Medical Technology HoldingsPHOENIX, AZ

1 program

CELZ-201-DDTN/A1 trial

Active Trials

NCT07137559Available

CuronixFL - Pompano Beach

1 program

PNS HFN/A1 trial

Active Trials

NCT03312010Completed38Est. Dec 2022

Colorado TherapeuticsCO - Louisville

1 program

Pain Reprocessing TherapyN/A1 trial

Active Trials

NCT06406699Completed46Est. Feb 2025

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

Daewon PharmaDW-330SR2

Colorado TherapeuticsPain Reprocessing Therapy

CuronixPNS HF

Clinical Trials (4)

Total enrollment: 250 patients across 4 trials

NCT02375633 Daewon PharmaDW-330SR2

Phase 3 Study of DW-330SR2 and Pelubiprofen in Chronic Back Pain Patients

Start: Apr 2014166 patients

Phase 3Completed

NCT07137559 Creative Medical Technology HoldingsCELZ-201-DDT

CELZ-201-DDT for the Treatment of Chronic Lower Back Pain

N/AAvailable

NCT06406699 Colorado TherapeuticsPain Reprocessing Therapy

Feasibility and Acceptability of Group Pain Reprocessing Therapy for Veterans With Chronic Neck/Back Pain

Start: Apr 2024Est. completion: Feb 202546 patients

N/ACompleted

NCT03312010 CuronixPNS HF

High Frequency PNS Stimulation Study for Back and Leg Pain

Start: Mar 2018Est. completion: Dec 202238 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.